公开(公告)号：US20190194698A1

公开(公告)日：2019-06-27

申请号：US16232614

申请日：2018-12-26

申请人： Erika Yoshida ,  Taek Soon Lee

发明人： Erika Yoshida ,  Taek Soon Lee

IPC分类号： C12P7/22 ,  C12N15/52

CPC分类号： C12P7/22 ,  C12N15/52 ,  C12N2510/02 ,  C12P13/22

摘要： The present invention provides for a composition comprising: (a) a first host cell capable of producing L-DOPA; and (b) a modified host cell is capable of converting L-DOPA into hydroxytyrosol (HTy); wherein any one or both of the first host cell and second host cell is a genetically modified host cell.

公开(公告)号：US06586444B2

公开(公告)日：2003-07-01

申请号：US10005645

申请日：2001-12-07

申请人： Rinta Ibuki ,  Fumio Shimojo ,  Satoshi Ueda ,  Toshihiko Toyoda ,  Masayuki Yamanaka ,  Erika Yoshida

发明人： Rinta Ibuki ,  Fumio Shimojo ,  Satoshi Ueda ,  Toshihiko Toyoda ,  Masayuki Yamanaka ,  Erika Yoshida

IPC分类号： A61K3144

CPC分类号： A61K9/0014 ,  A61K31/40 ,  A61K31/436 ,  A61K47/08 ,  A61K47/14 ,  A61K47/32 ,  A61K47/38 ,  C07D498/04 ,  Y10S514/947

摘要： To provide a pharmaceutical composition comprising a macrolide compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.

公开(公告)号：US06673808B1

公开(公告)日：2004-01-06

申请号：US09673260

申请日：2000-11-22

申请人： Rinta Ibuki ,  Fumio Shimojo ,  Satoshi Ueda ,  Toshihiko Toyoda ,  Masayuki Yamanaka ,  Erika Yoshida

发明人： Rinta Ibuki ,  Fumio Shimojo ,  Satoshi Ueda ,  Toshihiko Toyoda ,  Masayuki Yamanaka ,  Erika Yoshida

IPC分类号： A61K3144

CPC分类号： A61K9/0014 ,  A61K31/40 ,  A61K31/436 ,  A61K47/08 ,  A61K47/14 ,  A61K47/32 ,  A61K47/38 ,  C07D498/04 ,  Y10S514/947

摘要： To provide a pharmaceutical composition comprising a macrolide compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stability and absorption kinetics and/or a low irritation potential.

摘要翻译： 提供包含大环内酯化合物如三环化合物（I）或其药学上可接受的盐，溶解/吸收促进剂，药物基质和任选的相容剂和/或增稠剂的药物组合物。 其稳定性和吸收动力学和/或低刺激潜力令人满意。